|
|
Dr Hannah Kettler
Director, Global Health Policy & Advocacy
Bill and Melinda Gates Foundation
Christian Loucq
Malaria Vaccine Initiative
Ian Barr
Director
Centre for Influenza
Dr Jeffrey Ulmer
Global Head of External Research
Novartis
Dr Ian Frazer
Director
Diamantina Institute for Cancer
|
Conference:
Day 1
14th Oct 9am - 5:30pm
Day 2
15th Oct 9am - 5:30pm
Workshops: 13th Oct 9am - 5pm
"Practical Application of Risk Management in Vaccine
Compliance and Quality Assurance"
Led by: StephenWilliams, Director, SeerPharma
» Full conference programme
|
|
|
|
Meet our speakers...
|
Dr Ian Barr
Deputy Director
WHO Collaborating Centre for Reference and Research on Influenza
|
|
Dr Barr has over 30 years experience in R&D both in academic institutes and at CSL in vaccine development, mucosal immunology, adjuvants and cancer therapeutics. The WHO Collaborating Centre for Influenza is one of four in the world and plays an active role in regional influenza surveillance, WHO influenza vaccine formulation and testing and pandemic planning with various state and federal bodies.
|
|
|
Prof Allan Cripps
Pro Vice Chancellor Health
Griffith University
|
|
Professor Cripps is a recognised expert in the area of mucosal immunology. He had 20 years' experience in the Health and Pharmaceutical industries before becoming a full-time academic where he has continued research in the fields of human infectious diseases and mucosal immunity. Whilst working in the pharmaceutical industry his main areas of responsibilities were to manage intellectual property and patenting as well as directing research towards oral immunization against a range of bacterial pathogens, particularly of the respiratory tract.
|
 |
|
Ian Denney
Manager Veterinary Services
Animal Health Australia
|
|
|
 |
|
Stanley Erck
Chief Executive Officer
IOMAI
|
|
Stanley has held senior management positions in the biotechnology and healthcare industry for over 25 years. As president and CEO of Iomai since 2000, he has led the company through an IPO and the development of a late stage clinical product. He has successfully brought products into late stage clinical trials and negotiated major alliances with pharmaceutical and biotechnology companies.
|
 |
|
Prof Ian Frazer
Director Diamantina Institute for Cancer, Immunology and Metabolic Medicine
University of Queensland
|
|
Dr Frazer is a named inventor of HPV prophylactic and therapeutic vaccines licensed to CSL, Merck and GSK. He has sat on various committees of the National Health and Medical Research Council of Australia continuously over the last 15 years, advises the WHO on papillomavirus vaccines and was chosen as the 2006 Australian of the Year.
|
|
|
Karen Gibson
General Manager
National eHealth Transition Authority
|
|
Karen coordinates NEHTA's work across the Clinical and Medicines Terminologies, Medicines Directory, Clinical Information and Health Record Design initiatives. Karen has over 20 years experience in the health and medical research sectors, with particular interest in electronic health records and strategic information management, and has worked in the strategic planning sections of both Queensland Health and the Department of Human Services Victoria.
|
 |
|
Andrew Goodsall
Senior Healthcare Analyst
UBS
|
|
Andrew is the senior healthcare analyst with UBS Australia. He and his team have been rated the number one healthcare equities research team in each of the major surveys since 2003. Until 1999 he was senior adviser/chief of staff to the health minister in the Kennett Government, with responsibilities for advice on 120 public hospitals, episodic funding, medical research funding and privatisation programmes.
|
 |
|
Dr Daniel Grant
Head of Strategic Alliances ANZ
Pfizer
|
|
In collaboration with colleagues in Pfizer's Worldwide Business Development team, Dan is responsible for identifying and managing collaborative opportunities that arise from Australia's research landscape that align with Pfizer's strategic direction. Prior to joining Pfizer, Dr Grant was a senior business development manager at Melbourne Ventures and a business development manager for Biocomm Services.
|
 |
|
Dr Ian Gust
Chair Scientific Advisory Board
International AIDS Vaccine Initiative
|
|
Ian is a medical virologist who serves on the Boards of the Australian International Health Institute, the International Vaccine Institute and consults for WHO the European Commission and the World Bank. During his career Ian was R&D Director at CSL, founded and directed the Macfarlane Burnet Institute for Medical Research, established the National HIV reference laboratory and directed the NHMRC special unit for AIDS virology.
|
 |
|
Dr Hannah Kettler
Director
Bill and Melinda Gates Foundation
|
|
Hannah is responsible for a portfolio of grants that aim to secure financing and policy support for global health product innovation. Her work is focused on reducing risks and designing of financial incentives and business models to encourage private sector engagement. Her work for the Association for British Pharmaceutical Industry focused on the economics of innovation in the pharmaceutical industry.
|
 |
|
Assoc Prof Rajiv Khanna
Head, Tumour Immunology Laboratory
Queensland Institute of Medical Research
|
|
Rajiv heads the Tumour Immunology Laboratory at QIMR. Over the last few years, he has successfully translated his research to the development of novel immunotherapeutic strategies for the treatment of human cytomegalovirus and Epstein-Barr virus-associated diseases. He was awarded NH&MRC R Douglas Wright Fellowship in 1997 and more recently appointed as Principal Research Fellow.
|
 |
|
Dr Christian Loucq
Director
PATH Malaria Vaccine Initiative
|
|
Dr. Loucq has more than 30 years of experience in medicine, pharmaceuticals, vaccines, and global health. He has managed vaccine businesses in China, India, and Thailand and worked with large vaccine companies, such as GlaxoSmithKline and Sanofi Pasteur, and biotech companies including Rhein Biotech and Acambis. He has extensive experience partnering with local governments, building public-private partnerships, and setting up local private collaborations.
|
|
|
Prof Nikolai Petrovsky
Medical Centre
Flinders Medical Centre
|
|
Nikolai is Chairman of Vaxine Pty Ltd, Professor of Medicine at Flinders University, Director of Endocrinology at Flinders Medical Centre, and Secretary-General of the International Immunomics Society. He is known internationally for his vaccine adjuvant research, being principal investigator on a NIH bioterrorism grant and having personally taken three novel vaccines from the laboratory into human trials.
|
 |
|
Dr Satish Ravetkar
Senior Director
Serum Institure of India
|
|
Satish has over 35 years experience in manufacturing, quality assurance, projects & materials and technology transfer for vaccines & biopharmaceuticals. He is a member of the International Association for Pharmaceutical Science & Technology, the American Association of Pharmaceutical Scientists, the European Federation of Biotechnology and the Pharmaceutical Manufacturers Association.
|
 |
|
Dr Klaus Stohr
Director, Influenza Vaccine Franchises
Novartis Vaccines & Diagnostics
|
|
In his role at Novartis Klaus coordinates the work of the Novartis Influenza Franchises core project teams on seasonal and pandemic influenza. Klaus has been Special Advisor on Influenza Pandemic Vaccine Development for the WHO Initiative for Vaccine Research, Coordinator of the WHO Global Influenza Program and Coordinator for WHO SARS Aetiology and Diagnosis Program.
|
 |
|
|
|
|
|
